Zhejiang Hisun Pharmaceutical
HISUN is one of the local leading pharmaceutical companies in China.
Launch date
Employees
Market cap
CAD1.6b
Enterprise valuation
CAD2.2b (Public information from Sep 2024)
Share price
CNY7.07 600267.SS
China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 11.4b | 12.1b | 12.0b | 10.4b | 9.3b | 9.8b | 10.0b |
| % growth | 3 % | 7 % | (1 %) | (14 %) | (10 %) | 5 % | 2 % |
| EBITDA | 2.2b | 2.1b | 2.1b | 1.5b | 1.8b | 1.7b | 1.7b |
| % EBITDA margin | 20 % | 17 % | 18 % | 15 % | 19 % | 18 % | 17 % |
| Profit | 417m | 487m | 489m | (93.2m) | 426m | 731m | 459m |
| % profit margin | 4 % | 4 % | 4 % | (1 %) | 5 % | 7 % | 5 % |
| EV / revenue | - | - | 1.1x | 1.5x | 0.9x | 0.9x | 0.9x |
| EV / EBITDA | - | - | 6.0x | 10.1x | 4.9x | 5.1x | 5.3x |
| R&D budget | 401m | 373m | 429m | 392m | - | - | - |
| R&D % of revenue | 4 % | 3 % | 4 % | 4 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Zhejiang Hisun Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
